中华微生物学和免疫学杂志
中華微生物學和免疫學雜誌
중화미생물학화면역학잡지
CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY
2013年
5期
375-378
,共4页
郭书英%汪模正%丁勇%孙思才
郭書英%汪模正%丁勇%孫思纔
곽서영%왕모정%정용%손사재
肠道病毒71型%中和抗体%免疫球蛋白
腸道病毒71型%中和抗體%免疫毬蛋白
장도병독71형%중화항체%면역구단백
Enterovirus type 71%Neutralizing antibody%Immunoglobulin
目的 考察献血员血浆中抗EV71中和抗体的状况,同时建立适宜的高通量筛选EV71特免血浆的方法,为制备EV71特异性免疫球蛋白提供技术支持.方法 以经典微量细胞病变中和方法测定血浆样品及市售普通静注丙种球蛋白中EV71抗体滴度,探索用于制备EV71特异性免疫球蛋白血浆的参考指标.据此,建立筛选血浆的高通量阈值中和方法,并与传统方法进行比较.应用筛选的EV71特免血浆制备EV71特免球蛋白,并应用细胞模型和动物模型评价其中和抗体活性.结果 以经典法检测,约20%的原料血浆中抗体滴度达1∶50或以上,混合后的效价为1∶180,达到市售普通静注丙种球蛋白的抗体水平.以480份样品检测,所建立的阈值法与经典方法符合率为88.1%;制备的EV71特免球蛋白质量符合国家标准,EV71中和活性比静注免疫球蛋白提高约16倍,对动物的保护作用显著提高.结论 成功建立了EV71特免血浆的筛选方法及血浆筛选参考指标;所建立的高通量筛选方法操作简便,可用于研制EV71特异性免疫球蛋白的血浆筛选;制备的EV71特免球蛋白中和效价显著提高,对动物的保护作用明显增强,对于重症手足口病的防治可能具有重要意义.
目的 攷察獻血員血漿中抗EV71中和抗體的狀況,同時建立適宜的高通量篩選EV71特免血漿的方法,為製備EV71特異性免疫毬蛋白提供技術支持.方法 以經典微量細胞病變中和方法測定血漿樣品及市售普通靜註丙種毬蛋白中EV71抗體滴度,探索用于製備EV71特異性免疫毬蛋白血漿的參攷指標.據此,建立篩選血漿的高通量閾值中和方法,併與傳統方法進行比較.應用篩選的EV71特免血漿製備EV71特免毬蛋白,併應用細胞模型和動物模型評價其中和抗體活性.結果 以經典法檢測,約20%的原料血漿中抗體滴度達1∶50或以上,混閤後的效價為1∶180,達到市售普通靜註丙種毬蛋白的抗體水平.以480份樣品檢測,所建立的閾值法與經典方法符閤率為88.1%;製備的EV71特免毬蛋白質量符閤國傢標準,EV71中和活性比靜註免疫毬蛋白提高約16倍,對動物的保護作用顯著提高.結論 成功建立瞭EV71特免血漿的篩選方法及血漿篩選參攷指標;所建立的高通量篩選方法操作簡便,可用于研製EV71特異性免疫毬蛋白的血漿篩選;製備的EV71特免毬蛋白中和效價顯著提高,對動物的保護作用明顯增彊,對于重癥手足口病的防治可能具有重要意義.
목적 고찰헌혈원혈장중항EV71중화항체적상황,동시건립괄의적고통량사선EV71특면혈장적방법,위제비EV71특이성면역구단백제공기술지지.방법 이경전미량세포병변중화방법측정혈장양품급시수보통정주병충구단백중EV71항체적도,탐색용우제비EV71특이성면역구단백혈장적삼고지표.거차,건립사선혈장적고통량역치중화방법,병여전통방법진행비교.응용사선적EV71특면혈장제비EV71특면구단백,병응용세포모형화동물모형평개기중화항체활성.결과 이경전법검측,약20%적원료혈장중항체적도체1∶50혹이상,혼합후적효개위1∶180,체도시수보통정주병충구단백적항체수평.이480빈양품검측,소건립적역치법여경전방법부합솔위88.1%;제비적EV71특면구단백질량부합국가표준,EV71중화활성비정주면역구단백제고약16배,대동물적보호작용현저제고.결론 성공건립료EV71특면혈장적사선방법급혈장사선삼고지표;소건립적고통량사선방법조작간편,가용우연제EV71특이성면역구단백적혈장사선;제비적EV71특면구단백중화효개현저제고,대동물적보호작용명현증강,대우중증수족구병적방치가능구유중요의의.
Objective To evaluate the titers of EV71 neutralizing antibody in donators' plasma,and to establish a high throughput screening method to screening anti-EV71 positive plasma for the production of EV7l-specific IVIG in practice.Methods The EV71 neutralizing antibody titers in plasma samples and in commercial IVIGs (intravenous immunoglobulins) were evaluated by micro-cytopathic effect neutralization test (MCPENT),and a selecting criteria was determined for screening anti-EV71 positive plasma.Then,a high throughput neutralizing method for screening plasma was established and a comparison with MCPENT was conducted.EV71-specific IVIG was prepared from screened anti-EV71 source plasma,and its neutralizing activity was evaluated in cell model and mouse model.Results The results of MCPENT showed that the titers of EVT1 neutralizing antibody were 1 ∶ 50 or above in 20% of the source plasma,and reached 1 ∶ 180 after being pooled,approaching to the titer of commercial IVIG.In 480 samples,the coincidence rate between the established high throughput neutralizing method and MCPENT was 88.1%.The quality of prepared EV71-specific IVIG was complied with the national standard,and its neutralizing potency was 16 times of that of IVIG,suggesting EV71-specific IVIG had a significantly improved protecting effect on experimental neonatal mice.Conclusion The screening method and the screening criteria for EV71 specific plasma were successfully established.The established high throughput neutralizing method that was operated easily could be used for plasma screening in the development of EV71-specific IVIG.The prepared EV71-specific IVIG,whose neutralizing potency was significantly improved,showed a markedly protective effect on experimental neonatal mice,suggesting it might be very important for the prevention and treatment of handfoot-and-mouth disease.